ES2529434T3 - Método para tratar neoplasias hematopoyéticas - Google Patents

Método para tratar neoplasias hematopoyéticas Download PDF

Info

Publication number
ES2529434T3
ES2529434T3 ES08851754.5T ES08851754T ES2529434T3 ES 2529434 T3 ES2529434 T3 ES 2529434T3 ES 08851754 T ES08851754 T ES 08851754T ES 2529434 T3 ES2529434 T3 ES 2529434T3
Authority
ES
Spain
Prior art keywords
combretastatin
hematopoietic neoplasms
treat hematopoietic
compound
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08851754.5T
Other languages
English (en)
Inventor
David Chaplin
Bronwyn G. Siim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxi Gene Inc
Original Assignee
Oxi Gene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxi Gene Inc filed Critical Oxi Gene Inc
Application granted granted Critical
Publication of ES2529434T3 publication Critical patent/ES2529434T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

Un compuesto de combretastatina, o una sal farmacéuticamente aceptable del mismo, para uso en el tratamiento de una neoplasia hematopoyética no sólida en el que la neoplasia hematopoyética es una neoplasia mieloide, y en el que el compuesto de combretastatina es el difosfato de combretastatina A-1 (CA1dP):**Fórmula** o una sal farmacéuticamente aceptable del mismo.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13

Claims (1)

  1. imagen1
ES08851754.5T 2007-11-21 2008-11-21 Método para tratar neoplasias hematopoyéticas Active ES2529434T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98978607P 2007-11-21 2007-11-21
US989786P 2007-11-21
PCT/US2008/084427 WO2009067706A1 (en) 2007-11-21 2008-11-21 Method for treating hematopoietic neoplasms

Publications (1)

Publication Number Publication Date
ES2529434T3 true ES2529434T3 (es) 2015-02-20

Family

ID=40667883

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08851754.5T Active ES2529434T3 (es) 2007-11-21 2008-11-21 Método para tratar neoplasias hematopoyéticas

Country Status (12)

Country Link
US (4) US20090192098A1 (es)
EP (1) EP2219451B1 (es)
JP (1) JP5302328B2 (es)
AU (1) AU2008326251B2 (es)
CA (1) CA2703283C (es)
DK (1) DK2219451T3 (es)
ES (1) ES2529434T3 (es)
HR (1) HRP20150040T1 (es)
PL (1) PL2219451T3 (es)
PT (1) PT2219451E (es)
SI (1) SI2219451T1 (es)
WO (1) WO2009067706A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070233391A1 (en) * 2002-03-07 2007-10-04 Cambridge University Technical Service Limited (CUTS) Scd fingerprints
US20090192098A1 (en) 2007-11-21 2009-07-30 Oxigene, Inc. Method for treating hematopoietic neoplasms
WO2012088438A1 (en) * 2010-12-22 2012-06-28 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
CN104276960B (zh) * 2014-09-26 2016-09-28 安徽省逸欣铭医药科技有限公司 盐酸他喷他多和塞来昔布共晶及其组合物和制备方法
EP3337495A4 (en) * 2015-08-18 2019-04-10 Mateon Therapeutics, Inc. USE OF VDA TO ENHANCE IMMUNOMODULATION THERAPIES AGAINST TUMORS
EP3700632A4 (en) * 2017-10-25 2021-08-25 Bionomics Limited METHOD OF TREATMENT OF ACUTE MYELOID LEUKEMIA
AU2020209767A1 (en) * 2019-01-15 2021-07-29 Ptc Therapeutics, Inc. Method for treating an acute myeloid leukemia

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4996237A (en) 1987-01-06 1991-02-26 Arizona Board Of Regents Combretastatin A-4
CA1338645C (en) 1987-01-06 1996-10-15 George R. Pettit Isolation, structural elucidation and synthesis of novel antineoplastic substances denominated "combretastatins"
US4940726A (en) 1989-04-26 1990-07-10 Arizona Board Of Regents Cell growth inhibitory macrocyclic lactones denominated Combretastatin D-1 and Combretastatin D-2
GB9106177D0 (en) 1991-03-22 1991-05-08 Aston Molecules Ltd Substituted diphenylethylenes and analogues or derivatives thereof
US5430062A (en) 1992-05-21 1995-07-04 Research Corporation Technologies, Inc. Stilbene derivatives as anticancer agents
US6908910B2 (en) 1993-08-06 2005-06-21 The Children's Medical Center Corporation Estrogenic compounds as anti-mitotic agents
TW325458B (en) 1993-09-08 1998-01-21 Ajinomoto Kk Stilbene derivatives and pharmaceutical compositions comprising the same for anti-cancer
US5731353A (en) 1993-09-08 1998-03-24 Ajinomoto Co., Inc. Stilbene derivatives and pharmaceutical compositions containing them
US5561122A (en) 1994-12-22 1996-10-01 Arizona Board Of Regents Acting On Behalf Of Arizona State University Combretastatin A-4 prodrug
TW334418B (en) 1995-03-07 1998-06-21 Ajinomoto Kk Stilbene derivatives and pharmaceutical compositions
EP1003498A4 (en) 1997-03-26 2004-07-14 Biosource Tech Inc DI-ARYL ETHERS AND DERIVATIVES THEREOF AS ANTI-CANCER AGENTS
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
WO1999034788A1 (en) 1998-01-09 1999-07-15 Arizona Board Of Regents, A Body Corporate, Acting On Behalf Of Arizona State University Synthesis of phenstatin and prodrugs thereof
JP2002500227A (ja) 1998-01-09 2002-01-08 アリゾナ ボード オブ リーゼンツ コンブレタスタチンａ−４プロドラッグとそのトランス異性体
GB2334256A (en) 1998-02-12 1999-08-18 Univ Montfort Hydroxylation activated prodrugs
US6433012B1 (en) 1998-03-25 2002-08-13 Large Scale Biology Corp. Method for inhibiting inflammatory disease
KR20010042168A (ko) 1998-03-25 2001-05-25 바이오소스 테크놀로지스 인코포레이티드 혈관형성을 저해하는 벤조에이트 유도체
ATE328599T1 (de) 1998-04-03 2006-06-15 Ajinomoto Kk Antitumorale mittel
WO2000006556A1 (en) 1998-07-27 2000-02-10 Abbott Laboratories Substituted oxazolines as antiproliferative agents
AU2190700A (en) 1998-12-17 2000-07-03 Tularik Inc. Tubulin-binding agents
GB9903404D0 (en) 1999-02-16 1999-04-07 Angiogene Pharm Ltd Methods of treatment and compositions useful for the treatment of diseases involving angiogenesis
GB9903403D0 (en) 1999-02-16 1999-04-07 Angiogene Pharm Ltd Substituted stilbene compounds with vascular damaging activity
JP2002537262A (ja) 1999-02-18 2002-11-05 オキシジェン，インコーポレイティド 血管破壊のターゲッティングに使用するための組成物および方法
CO5170498A1 (es) 1999-05-28 2002-06-27 Abbott Lab Biaril sulfonamidas son utiles como inhibidores de proliferacion celular
US6201001B1 (en) 1999-08-02 2001-03-13 Abbott Laboratories Imidazole antiproliferative agents
GB9918912D0 (en) 1999-08-12 1999-10-13 Angiogene Pharm Ltd New stilbenes with vascular damaging activity
US6849656B1 (en) 1999-09-17 2005-02-01 Baylor University Indole-containing and combretastatin-related anti-mitotic and anti-tubulin polymerization agents
WO2001068654A2 (en) * 2000-03-10 2001-09-20 Baylor University Tubulin binding ligands and corresponding prodrug constructs
GB0007401D0 (en) 2000-03-27 2000-05-17 Cancer Res Campaign Tech Substituted chalcones as therapeeutic compounds
ES2395097T3 (es) 2000-04-27 2013-02-08 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona En Nombre De Arizona State University Profármacos de Combretastatina A1 fosfato y Combretastatina B1 fosfato
CA2407672A1 (en) 2000-04-27 2001-11-01 Matthew P. Grealish Hydroxyphenstatin and the prodrugs thereof
CA2408220A1 (en) 2000-05-09 2001-11-15 George R. Pettit Antitubulin assembly and cell growth inhibitor denominated "dioxostatin"
MXPA02011218A (es) * 2000-05-15 2004-08-19 Celgene Corp Composiciones y metodos para el tratamiento de cancer.
JP2003535078A (ja) 2000-05-31 2003-11-25 アストラゼネカ アクチボラグ 血管損傷活性のあるインドール誘導体
US6720323B2 (en) 2000-07-07 2004-04-13 Angiogene Pharmaceuticals Limited Colchinol derivatives as angiogenesis inhibitors
US6743937B2 (en) * 2000-07-17 2004-06-01 Oxigene, Inc. Efficient method of synthesizing combretastatin A-4 prodrugs
GB0019944D0 (en) 2000-08-15 2000-09-27 Angiogene Pharm Ltd Compositions with vascular damaging activity
US6670344B2 (en) 2000-09-14 2003-12-30 Bristol-Myers Squibb Company Combretastatin A-4 phosphate prodrug mono- and di-organic amine salts, mono- and di- amino acid salts, and mono- and di-amino acid ester salts
AU2002216228A1 (en) 2000-12-21 2002-07-01 Cancer Research Ventures Limited Substituted stilbenes, their reactions and anticancer activity
US7037906B1 (en) 2000-12-22 2006-05-02 Oxigene, Inc. Methods for modulating tumor growth and metastasis
JP2004523517A (ja) * 2000-12-22 2004-08-05 ブリストル−マイヤーズ スクイブ カンパニー 腫瘍増殖および転移を調節するための方法
US20020183266A1 (en) * 2001-03-15 2002-12-05 Aventis Pharma, S.A. Combination comprising combretastatin and anticancer agents
GB2377469B (en) 2001-07-13 2005-07-06 Prismo Ltd Method and apparatus for laying a traffic calming surface
CA2463902A1 (en) 2001-10-26 2003-05-01 Oxigene, Inc. Functionalized stilbene derivatives as improved vascular targeting agents
GB0126889D0 (en) 2001-11-08 2002-01-02 Paterson Inst For Cancer Res Compounds and their uses
US7105695B2 (en) 2001-12-21 2006-09-12 Arizona Board Of Regents, Acting For And On Behalf Of Arizona State University Synthesis of combretastatin A-2 prodrugs
AU2003214462A1 (en) 2002-04-03 2003-10-13 Astrazeneca Ab Indole derivatives having anti-angiogenetic activity
US7358236B1 (en) * 2002-06-21 2008-04-15 Oxigene, Inc. Control of acute hypertension and cardiotoxicity in patients treated with vascular targeting agents
US20040024696A1 (en) 2002-08-02 2004-02-05 Federico Alves System for automatically transferring funds
TW549690U (en) 2002-11-13 2003-08-21 Tekcon Electronics Corp Electrical card connector
WO2004078126A2 (en) 2003-02-28 2004-09-16 Oxigene, Inc. Compositions and methods with enhanced therapeutic activity
ITRM20030355A1 (it) 2003-07-18 2005-01-19 Sigma Tau Ind Farmaceuti Composti ad attivita' citotossica derivati della combretastatina.
EP1896391B1 (en) 2005-06-14 2015-08-12 Baylor University Combretastatin analogs with tubulin binding activity
US20090192098A1 (en) 2007-11-21 2009-07-30 Oxigene, Inc. Method for treating hematopoietic neoplasms

Also Published As

Publication number Publication date
US9040500B2 (en) 2015-05-26
JP5302328B2 (ja) 2013-10-02
US20090264382A1 (en) 2009-10-22
EP2219451A4 (en) 2011-01-19
EP2219451B1 (en) 2014-11-12
CA2703283A1 (en) 2009-05-28
US20090192098A1 (en) 2009-07-30
WO2009067706A1 (en) 2009-05-28
AU2008326251A1 (en) 2009-05-28
HRP20150040T1 (hr) 2015-02-27
US20150246064A1 (en) 2015-09-03
US20120270831A1 (en) 2012-10-25
PT2219451E (pt) 2015-02-09
JP2011504510A (ja) 2011-02-10
CA2703283C (en) 2016-01-12
SI2219451T1 (sl) 2015-02-27
AU2008326251B2 (en) 2014-03-06
PL2219451T3 (pl) 2015-04-30
EP2219451A1 (en) 2010-08-25
DK2219451T3 (en) 2015-01-12

Similar Documents

Publication Publication Date Title
ES2529434T3 (es) Método para tratar neoplasias hematopoyéticas
AR077629A1 (es) Mimetico de smac
ES2665917T3 (es) Endoxifeno para su uso en el tratamiento del cáncer
CL2013002417A1 (es) Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas.
CR11510A (es) Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer
NI200900184A (es) Uso de compuestos inhibidores de quinaxolina de pi3k-alfa para el tratamiento del cáncer.
AR112532A2 (es) Compuestos de tetraciclina sustituidos con flúor en c7
PA8850801A1 (es) Compuestos útiles para inhibir chk1
NI201600022A (es) Compuestos terapéuticamente activos y sus métodos de uso
ECSP12011799A (es) Compuestos de espiropiperidina y uso farmacéutico de los mismos
ECSP099436A (es) Acilaminopirazoles como inhibidores de fgfr
ME00936B (me) Postupci liječenja kancera upotrebom piridopirimidinonskih inhibitora pi3k alfa
UY32153A (es) Inhibidores de piridomidinona de pi13ka(alfa) y mtor
UY32062A (es) Inhibidores de beta-secretasa
AR087107A1 (es) Compuesto inhibidor de la señalizacion de la trayectoria notch
UY39027A (es) Uso de favipiravir en el tratamiento de la infección por coronavirus
ES2563777T3 (es) Compuestos de nitrona para tratar la pérdida auditiva sensorineural
AR062394A1 (es) Uso de compuestos y derivados de 2,5-dihidroxibenceno para el tratamiento de la psoriasis
ES2552654T3 (es) Uso de LCAT para tratar la anemia y la disfunción de los glóbulos rojos
PE20170148A1 (es) Compuestos de 1,3, 4-tiadiazol y uso de los mismos para el tratamiento del cancer
CO6321285A2 (es) Uso de 3,11b-cis- dihidrotetrabenazina en el tratamiento de la esclerosis multiple y la mielitis autoinmunitaria
SV2018005702A (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
AR095015A1 (es) Compuestos de azetidiniloxifenilpirrolidina
AR090806A1 (es) Glucosidos de pirazol y su utilizacion en el tratamiento de la diabetes tipo i y ii
AR087902A1 (es) COMPOSICIONES Y METODOS PARA TRATAR EL CANCER USANDO EL INHIBIDOR DE PI3Kb Y EL INHIBIDOR DE LA VIA DE MAPK, INCLUIDOS LOS INHIBIDORES DE MEK Y RAF